NASDAQ:VERU

Veru (VERU) Stock Forecast, Price & News

$1.04

+0.01 (+0.97%)

(As of 05/26/2023 04:00 PM ET)

Compare

Today's Range: $1.02
▼
$1.10
50-Day Range: $1.00
▼
$1.59
52-Week Range: $0.93
▼
$24.55

Volume: 1.33 million shs
Average Volume: 1.75 million shs
Market Capitalization: $92.81 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.67

Veru MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,214.1% Upside
$13.67 Price Target
Short Interest: Bearish
21.96% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.77
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.32) to ($0.89) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

762nd out of 1,009 stocks

Pharmaceutical Preparations Industry

385th out of 494 stocks

3.5

Analyst's Opinion

Consensus Rating
Veru has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.67, Veru has a forecasted upside of 1,214.1% from its current price of $1.04.
Amount of Analyst Coverage
Veru has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
21.96% of the float of Veru has been sold short.
Short Interest Ratio / Days to Cover
Veru has a short interest ratio ("days to cover") of 5.1.
Change versus previous month
Short interest in Veru has recently increased by 2.83%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Veru does not currently pay a dividend.
Dividend Growth
Veru does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VERU.

1.5

News and Social Media Coverage

News Sentiment
Veru has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Veru this week, compared to 5 articles on an average week.
Search Interest
Only 14 people have searched for VERU on MarketBeat in the last 30 days. This is a decrease of -74% compared to the previous 30 days.
MarketBeat Follows
Only 7 people have added Veru to their MarketBeat watchlist in the last 30 days. This is a decrease of -56% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Veru insiders have not sold or bought any company stock.
Percentage Held by Insiders
23.90% of the stock of Veru is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
48.87% of the stock of Veru is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Veru are expected to grow in the coming year, from ($1.32) to ($0.89) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Veru is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Veru is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Veru has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Veru (NASDAQ:VERU) Stock

Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer, VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer, and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT. The firm's breast cancer drug candidates include: Enobosarm, an oral, new chemical entity, selective androgen receptor agonist that targets the androgen receptor in AR+/ER+/HER2-hormone sensitive metastatic breast cancer without unwanted virilizing side effects, and VERU 111 for triple negative metastatic breast cancer that has become resistant to taxane IV chemotherapy. It is also advancing the new drug formulation TADFYN, tadalafil and fin

Receive VERU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.

VERU Stock News Headlines

May 24, 2023 | finance.yahoo.com

Veru to Present at the Jefferies Healthcare Conference

May 20, 2023 | americanbankingnews.com

HC Wainwright Equities Analysts Decrease Earnings Estimates for Veru Inc. (NASDAQ:VERU)

May 30, 2023 | Edge On The Street (Ad)

How to Invest in AI's Fast-Growing Market

The AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.

May 15, 2023 | msn.com

HC Wainwright & Co. Maintains Veru (VERU) Buy Recommendation

May 15, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Veru (VERU)

May 15, 2023 | americanbankingnews.com

Veru (NASDAQ:VERU) PT Lowered to $2.00

May 12, 2023 | finanznachrichten.de

Veru Inc.: Veru Reports Fiscal 2023 Second Quarter Financial Results

May 12, 2023 | msn.com

Veru Q2: Revenue Halves, Prioritizes Clinical Programs, Wider Loss & More

May 30, 2023 | Edge On The Street (Ad)

How to Invest in AI's Fast-Growing Market

May 11, 2023 | finance.yahoo.com

Veru Inc. (VERU) Reports Q2 Loss, Tops Revenue Estimates

May 11, 2023 | msn.com

Veru: Q2 Earnings Insights

May 11, 2023 | markets.businessinsider.com

VERU Stock Earnings: Veru Misses EPS, Beats Revenue Estimates

May 11, 2023 | finance.yahoo.com

Veru Reports Fiscal 2023 Second Quarter Financial Results

May 10, 2023 | markets.businessinsider.com

Analyst Ratings for Veru

May 10, 2023 | msn.com

A Preview Of Veru's Earnings

May 10, 2023 | msn.com

Veru Q2 2023 Earnings Preview

May 9, 2023 | finance.yahoo.com

Is a Surprise Coming for Veru (VERU) This Earnings Season?

May 9, 2023 | americanbankingnews.com

Veru (VERU) Set to Announce Quarterly Earnings on Thursday

May 4, 2023 | finance.yahoo.com

Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS

May 4, 2023 | finance.yahoo.com

Veru Inc. (VERU) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

May 3, 2023 | finance.yahoo.com

Veru Enters into Common Stock Purchase Agreement for Up to $100 Million with Lincoln Park Capital

April 30, 2023 | americanbankingnews.com

Q2 2023 Earnings Estimate for Veru Inc. (NASDAQ:VERU) Issued By HC Wainwright

April 29, 2023 | americanbankingnews.com

Veru Inc. (NASDAQ:VERU) Receives Consensus Rating of "Buy" from Analysts

April 27, 2023 | finance.yahoo.com

Veru to Report Fiscal 2023 Second Quarter Financial Results on May 11, 2023

April 20, 2023 | finance.yahoo.com

Veru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones

April 19, 2023 | finance.yahoo.com

Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom® in U.S. Public Health Sector

April 15, 2023 | americanbankingnews.com

Veru (NASDAQ:VERU) Receives Buy Rating from HC Wainwright

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive VERU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.

VERU Company Calendar

Last Earnings: 12/02/2021
Today: 5/30/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 9/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Personal Products
Sector: Medical
Current Symbol: NASDAQ:VERU
CUSIP: 31446210
CIK: 863894
Web: www.veruhealthcare.com
Phone: (305) 509-6897
Fax: 312-595-9122
Employees: 252
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $13.67
High Stock Price Forecast: $30.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +1,214.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.73)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-83,780,000.00
Net Margins: -652.36%
Pretax Margin: -652.29%
Return on Equity: -206.09%
Return on Assets: -115.37%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.10
Quick Ratio: 0.91

Sales & Book Value

Annual Sales: $39.35 million
Price / Sales: 2.36
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.01 per share
Price / Book: 1.03

Miscellaneous

Outstanding Shares: 89,240,000
Free Float: 67,909,000
Market Cap: $92.81 million
Optionable: Optionable
Beta: -0.22

Key Executives

Mitchell Shuster Steiner
Chairman, President & Chief Executive Officer

Michele Greco
Chief Financial & Administrative Officer

Robert H. Getzenberg
Executive Vice President-Medical Affairs

Domingo Rodriguez
Executive Vice President-Clinical Operations

K. Gary Barnette
Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VERU Stock - Frequently Asked Questions

Should I buy or sell Veru stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veru in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VERU shares.
View VERU analyst ratings or view top-rated stocks.
What is Veru's stock price forecast for 2023?: 2 Wall Street research analysts have issued twelve-month price objectives for Veru's shares. Their VERU share price forecasts range from $2.00 to $30.00. On average, they predict the company's share price to reach $13.67 in the next year. This suggests a possible upside of 1,214.1% from the stock's current price.
View analysts price targets for VERU or view top-rated stocks among Wall Street analysts.
How have VERU shares performed in 2023?: Veru's stock was trading at $5.28 at the start of the year. Since then, VERU shares have decreased by 80.3% and is now trading at $1.04.
View the best growth stocks for 2023 here.
When is Veru's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our VERU earnings forecast.
How were Veru's earnings last quarter?: Veru Inc. (NASDAQ:VERU) issued its earnings results on Thursday, December, 2nd. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.04. The business had revenue of $15.65 million for the quarter, compared to analysts' expectations of $18.26 million. Veru had a negative trailing twelve-month return on equity of 206.09% and a negative net margin of 652.36%. During the same quarter last year, the business earned ($0.01) earnings per share.
What ETFs hold Veru's stock?: ETFs with the largest weight of Veru (NASDAQ:VERU) stock in their portfolio include Vanguard Consumer Staples ETF (VDC), Fidelity MSCI Consumer Staples Index ETF (FSTA) and Carbon Collective Climate Solutions U.S. Equity ETF (CCSO).

What other stocks do shareholders of Veru own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Kadmon (KDMN), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Matinas BioPharma (MTNB), Organigram (OGI), Vaxart (VXRT), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).
What is Veru's stock symbol?: Veru trades on the NASDAQ under the ticker symbol "VERU."
Who are Veru's major shareholders?: Veru's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.29%), Perceptive Advisors LLC (4.82%), Geode Capital Management LLC (1.29%), Two Sigma Investments LP (0.89%), Renaissance Technologies LLC (0.62%) and Squarepoint Ops LLC (0.53%). Insiders that own company stock include Harry Fisch, K Gary Barnette, Lucy Lu, Mario Eisenberger, Michele Greco and Mitchell Shuster Steiner.
View institutional ownership trends.
How do I buy shares of Veru?: Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Veru's stock price today?: One share of VERU stock can currently be purchased for approximately $1.04.
How much money does Veru make?: Veru (NASDAQ:VERU) has a market capitalization of $92.81 million and generates $39.35 million in revenue each year. The company earns $-83,780,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis.
How many employees does Veru have?: The company employs 252 workers across the globe.
How can I contact Veru?: Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The official website for the company is www.veruhealthcare.com. The company can be reached via phone at (305) 509-6897, via email at veruinvestor@verupharma.com, or via fax at 312-595-9122.

This page (NASDAQ:VERU) was last updated on 5/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial